A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Dementia, Alzheimer Type Clinical Trial

— XanADu  

Official title:

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02727699
• Other study ID #: ACW0002
• Status: Completed
• Phase: Phase 2
• Start date: March 23, 2017
• Est. completion date: March 15, 2019

Study information

• Verified date: April 2022
• Source: Actinogen Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem™ in subjects with mild dementia due to Alzheimer's Disease. Subjects will be randomized to receive either 10mg once daily Xanamem™ or Placebo at a 1:1 ratio in a double-blinded fashion.

Description:

This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem™ once daily in adult subjects with mild dementia due to AD.

Based on Xanamem™'s mode of action on hippocampal function, amnestic symptoms may respond best, thus favouring the inclusion of mild dementia due to AD, with given evidence of disease progression. Subjects will be treated in a double-blind fashion, where both the investigators and subjects will be unaware of the treatment assignments, to minimise any subjective or unrecognised bias carried by the investigators and subjects. Placebo will be used as the comparator in this study.

It is planned to randomise approximately 174 subjects at approximately 25 study sites in three countries (Australia, United Kingdom, and United States), with the aim to enrol 7 to 10 subjects at each study site. Subject enrolment will be competitive but a cap of 20 subjects per study site is to be established to avoid any side effects. In case the sample composition at one study site is creating concerns, an enrolment stop can also occur at fewer than 20 subjects.

At study end, a total of 185 subjects were randomised into this study and received active treatment.

The data safety monitoring board (DSMB) will periodically meet for the review of accumulating safety study data and will also be involved in the interim analysis.

At the Baseline visit (Week 0), eligible subjects will be randomised on a 1:1 ratio to receive either Xanamem™ administered orally once daily (QD) for the treatment group or matching placebo for the placebo group. Subjects will return to the study site for visits at Week 4 and Week 8, End of Treatment (Week 12) and Follow-up (4 weeks post last dose of study drug) visits, at which study assessments will be performed.

Ad hoc telephone contact may also occur at any other time-point throughout the study, if deemed necessary by the investigator/study nurse, or if the subject wishes to report an Adverse Event (AE)

Subjects will be interviewed and examined at the study site at each visit and will complete a variety of questionnaires and routine safety evaluations.

Optional Pharmacodynamic (PD) sampling will be performed at specific visits. Subjects who do not provide consent for this optional sub-study will still be eligible for the main study.

The overall study duration for an individual subject will be 17 to 20 weeks, including a screening period of one to 4 weeks, a double-blind treatment period of 12 weeks, and a follow-up period of 4 weeks. The total duration of the study is expected to be 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: March 15, 2019
• Est. primary completion date: March 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Males and females aged 50 years or older at the time of informed consent.

2. Female Subjects:

1. Post menopausal women, defined as no menses for 12 months without an alternative medical cause. If there is any concern about the menopausal status of a prospective female subject, a follicle stimulating hormone test (FSH) should be requested to confirm post-menopausal status. Post menopausal women confirmed by FSH level > 40 mIU (milli-international units per milliliter) /mL, will be confirmed by central laboratory.

2. Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and Baseline, and be willing to use highly effective methods of contraception from the Screening visit until 3 months after last dose of study drug. If re-test is required, a local urine pregnancy test will be performed at Baseline to determine if the subject can continue to randomisation.

3. Are permanently sterile or have had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy.

4. Women must not be breastfeeding.

3. Male Subjects:

1. Who are sexually active, fertile men must use highly effective methods of contraception from Day 1 until 3 months after last dose of study drug if their partners are WOCBP.

2. Who are permanently sterile or have had bilateral orchiectomy.

4. Diagnosis of mild dementia due to Alzheimer's disease (AD) with increased level of certainty (provided by evidence of clinical deterioration within the 6 months preceding Screening, as assessed by the investigator) as determined by the National Institute of Ageing (NIA) and the Alzheimer's Association (AA) workgroup.

5. Mild dementia due to probable AD with Mini-Mental Status Examination (MMSE) 20 to 26 (inclusive).

6. Clinical Dementia Rating Scale (CDR) Global Score of 0.5 to 1.0.

7. A brain magnetic resonance imaging (MRI) or computed tomography (CT) scan in the 12 months preceding Screening that in the investigator's opinion is consistent with AD as the principle aetiology of the dementia with no other clinically significant abnormality, e.g. another principle underlying aetiology of the subject's dementia, or a lesion which could affect cognition e.g. a brain tumour or large stroke.

8. On stable dose of acetylcholinesterase (AChEI) and/or memantine (at least 3 months prior to Screening) OR treatment-naïve. Initiating AChEIs or memantine during the study will not be permitted.

9. Apart from a clinical diagnosis of mild dementia due to AD, the subject must be in good health as determined by the investigator, based on medical history and screening assessments.

10. Has a consenting study partner who, in the investigator's judgement, has frequent and sufficient contact with the subject to be able to provide accurate information as to the subject's cognitive and functional abilities. The study partner must be available to provide information to the investigator and study site staff about the subject and agrees to attend all study site visits in person for scale completion. A study partner should be available for the duration of the study. The measure of adequate availability will be at the investigator's discretion.

11. Must be willing and able to comply with the requirements of the protocol and must be available to complete the study.

12. Must satisfy a medical examiner about their fitness to participate in the study.

13. Must provide written informed consent to participate in the study.

Exclusion Criteria:

1. Clinically significant abnormalities in vital signs (blood pressure, heart rate, respiration rate and oral temperature), as determined by the investigator.

2. Clinically significant abnormal haematology, biochemistry and urine examination values, specifically abnormal liver and renal function and Vitamin B12 levels below lower threshold since these parameters may impact cognitive function, as determined by the investigator.

3. Has had a significant systematic illness or infection within the past 4 weeks prior to randomisation, as determined by the investigator.

4. Clinically significant neurological disease other than AD, such as (but not limited to) Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural haematoma, multiple sclerosis or a history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

5. Subjects with clinical evidence of peripheral neuropathy or historical evidence of clinically significant nerve conduction abnormalities.

6. Has had a stroke within the year prior to randomisation, as determined by the investigator.

7. Has a lifetime diagnosis of a major psychiatric disorder (other than dementia), based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. This includes but is not limited to schizophrenia, schizoaffective disorder, bipolar affective disorder, alcohol dependence syndrome or major depressive disorder.

8. Has a history of disease directly related to the hypothalamus, the pituitary and/or the adrenal glands which affect the hypothalamic-pituitary-adrenal axis function.

9. Has uncontrolled clinical conditions relating to glucose and lipid metabolism.

10. Clinically significant electrocardiogram (ECG) abnormalities, including Corrected QT interval (QTc) > 450 ms, following ECG tracings at Screening.

11. Use of any prohibited medication as detailed in the study protocol.

12. Participation in another clinical study of an investigational drug or device whereby the last investigational drug/device administration is within 60 days of Screening.

13. Inability to communicate well with the investigator (i.e. language problem, non-fluent English [as scales will be provided in English only], poor mental development or impaired cerebral function).

14. Subject will undergo the tests, Alzheimer's Disease Assessment Scales (ADAS)-Cog v14, CDR-Sum of Boxes (SOB), MMSE, Neuropsychological Test Battery (NTB; executive domain) and RAVLT at the indicated time-points to avoid uncontrolled learning effects. Subjects who need to perform these tests externally to and in parallel with this study will be excluded.

15. Subject has ingested any food or drink containing grapefruit, Seville oranges, star fruit or derived products (e.g. fruit juice), for at least 3 days prior to the first administration of study drug.

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia
• Dementia, Alzheimer Type

Intervention

Drug:
• Xanamem™
Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
• Placebo (for Xanamem™)
Excipient blend capsules manufactured to mimic Xanamem™ capsules

Locations

Country	Name	City	State
Australia	Central Coast Neurosciences Research	Central Coast	New South Wales
Australia	St Vincent's Hospital Sydney	Darlinghurst	New South Wales
Australia	Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health	Heidelberg West	Victoria
Australia	KaRa Institute of Neurological Diseases	Macquarie Park	New South Wales
Australia	Australian Alzheimer's Research Foundation	Nedlands	Western Australia
United Kingdom	The Research Institute for the Care of Older People	Bath	Combe Park
United Kingdom	Institute of Clinical Sciences, Queen's University Belfast	Belfast	Northern Ireland
United Kingdom	Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh	Edinburgh
United Kingdom	West London Mental Health Trust	Isleworth	London
United Kingdom	St Pancras Clinical Research	Kings Cross	London
United Kingdom	Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital	Manchester	Lancashire
United States	Atlanta Center for Medical Research	Atlanta	Georgia
United States	Research Alliance Inc.	Clearwater	Florida
United States	NeuroStudies.Net, LLC	Decatur	Georgia
United States	The Clinical Trial Center	Jenkintown	Pennsylvania
United States	National Research Institute	Los Angeles	California
United States	The Neurology Research Group, LLC	Miami	Florida
United States	The NeuroCognitive Institute	Mount Arlington	New Jersey
United States	Compass Research LLC	Orlando	Florida
United States	IMIC, Inc.	Palmetto Bay	Florida
United States	PCND Neuroscience Research Institute	Poway	California
United States	PMG Research of Rocky Mount, LLC	Rocky Mount	North Carolina
United States	Pacific Research Network, Inc.	San Diego	California
United States	Richmond Behavioral Associates	Staten Island	New York
United States	Tucson Neuroscience Research, LLC	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Actinogen Medical	ICON Clinical Research

Countries where clinical trial is conducted

United States,  Australia,  United Kingdom, 

References & Publications (1)

Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) inhibitor UE2343 (Xanamem™). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pregnancy Test	Women of childbearing potential only. Serum pregnancy test at screening and a urine pregnancy test at all subsequent clinic visits	Screening, baseline, Week 4, Week, 8, Week 12, Week 16
Other	Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Testosterone	This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit	Screening, baseline, Week 4, Week, 8, Week 12, Week 16
Other	Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Androstenedione	This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit	Screening, baseline, Week 4, Week, 8, Week 12, Week 16
Other	Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Dehydroepiandrosterone Sulfate (DHEAS)	This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit	Screening, baseline, Week 4, Week, 8, Week 12, Week 16
Other	Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Adrenocorticotropic Hormone (ACTH)	This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit	Screening, baseline, Week 4, Week, 8, Week 12, Week 16
Other	Change in Pharmacokinetics (PK), Including Analysis of Cortisol Levels	This assessment will be carried out on subjects who consented to this optional test. PD sample will be collected at pre-dose at each required visit	Baseline, Week 4, Week 8, Week 12 and Unscheduled Safety Visit
Other	NTSS-6	Change in Neuropathy Total Symptom Score (NTSS-6)	Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc and Unscheduled Safety Visit
Other	NFM	Change in Nerve Function Monitoring (NFM)	Screening, Baseline, Week 4, Week 8, Week 12, Week 16
Other	Vital Signs	Change in Vital Signs (including Heart Rate, Blood Pressure, Body Weight, BMI)	Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Unscheduled Safety Visit
Other	Metabolic Function	Change in Metabolic Function Test Results of Lipids, Glucose, Hemoglobin A1c (HbA1c)	Baseline, Week 12
Other	Clinical Safety Laboratory Values	Change in Clinical Safety Laboratory Values (biochemistry, hematology, urine examination)	Screening, Baseline, Week 4, Week 8, Week 12, Week 16
Other	AEs	Incidence of Adverse Events (AEs)	Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc
Other	ECG	Change in Electrocardiogram (ECG) Values	Screening, Baseline, Week 4, Week 8, Week 12, Week 16
Other	CSSRS	Change in Scores of Columbia Suicide Severity Rating Scale (CSSRS)	Screening, Week 4, Week 8, Week 12, Week 16
Primary	ADAS-Cog v14	Change in Alzheimer's Disease Assessment Scales - Cognitive Subscale Score, version 14 (ADAS-Cog v14) Total scores of ADAS Cog 14 range from 0 to 90, with higher scores indicating greater disease severity.	Baseline, Week 12
Primary	AD COMposite Scores	Change in AD COMposite Scores (ADCOMs- ADCOMs, composite score is derived from a weighted linear combination of items from commonly used outcome scales Cognitive Subscale Version 14 [ADAS-Cog v14], Clinical Dementia Rating Scale - Sum of Boxes [CDR-SOB], and Mini-Mental Status Examination [MMSE]. Th ADCOMs range: 0 - 1.97, whereas a lover score is interpreted as a better result.; Included scales: ADAS-Cog v14 (range: 0-90): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.; CDR-SOB (range: 0-18): A lower score is indicative of better cognition, a higher score indicates higher cognitive impairment.; MMSE (range: 0-30): A higher score is indicative of better cognition, a lower score indicates higher cognitive impairment.	Baseline, Week 12
Secondary	RAVLT	Change in Rey Auditory Verbal Learning Test (RAVLT) RAVLT will be administered using five trials, with individual scores from 0-15. The total score is the combined score of all five trials, ranging from 0 to 75, whereas a lower score is considered a worse outcome and a higher score a better outcome.	Baseline, Week 12
Secondary	CDR-SOB	Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB) The CDR is obtained through semi-structured interviews of patients and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.; Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment.; The CDR-SOB is based on summing each of the domain box scores, with scores ranging from 0-18, whereas lower scores represent better outcomes and higher scores worse outcomes.	Baseline, Week 12
Secondary	MMSE	Change in Mini-Mental Status Examination (MMSE) MMSE total score (0 - 30) is a sum of all 30 point questionnaire of MMSE. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.	Baseline, Week 12
Secondary	NPI (Neuropsychiatric Inventory)	Change in Neuropsychiatric Inventory (NPI) The NPI includes questions to ten behavioural and two neurodegenerative domains.; Raters recorded neuropsychiatric symptoms using a 1-4 scale for frequency and a 1-3 scale for severity for each item in the instrument, with the score for each domain being: domain score = frequency x severity.; The total score is calculated by adding the scores of the first 10 domain scores.; The two neurodegenerative items are not included in the NPI total score as they form part of the depression syndrome in some patients and were specifically excluded from the dysphoria subscale of the NPI in order to allow that subscale to focus on mood symptoms.; The total NPI-score minimum is 0 and the maximum 144. A lower score is considered a better outcome, a higher score a worse outcome.	Baseline, Week 12
Secondary	NTB - Executive Domain	Change in Neuropsychological Test Batteries (NTB) - Executive Domains: Controlled Oral Word Association - Test (COWAT) and Total Correct Response (CFT) Total NTB score is the sum of COWAT and CFT. During the COWAT test, the subject is asked to mention as many words as possible beginning with different letters (F, A, S) within 1 minute each. The number of words for each letter is recorded, the score is the sum of all words. There is no minimum or maximum score, whereas more words indicate a better outcome.; During the CFT test, the subject is given 1 minute to produce as many unique words as possible within a semantic category. The subject's score is the number of unique correct words.; There is no minimum or maximum score whereas a score of under 14 is interpreted as concerning regarding cognition.	Baseline, Week 12

External Links

•   Selection and early clinical evaluation of the brain-penetrant 11ß-hydroxysteroid dehydrogenase type 1(11ß-HSD1) inhibitor UE2343 (Xanamem™)